Cancer Research Landon Prizes for Basic and Translational Cancer Research  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swift, L. P.
Right arrow Articles by Cutts, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swift, L. P.
Right arrow Articles by Cutts, S. M.
[Cancer Research 66, 4863-4871, May 1, 2006]
© 2006 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death

Lonnie P. Swift1, Ada Rephaeli2, Abraham Nudelman3, Don R. Phillips1 and Suzanne M. Cutts1

1 Department of Biochemistry, La Trobe University, Victoria, Australia; 2 Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel; and 3 Chemistry Department, Bar Ilan University, Ramat Gan, Israel

Requests for reprints: Don R. Phillips, Department of Biochemistry, La Trobe University, Victoria, 3086, Australia. Phone: 61-3-94792182; Fax: 61-3-94792467; E-mail: d.phillips{at}latrobe.edu.au.

Doxorubicin (Adriamycin) is one of the most commonly used chemotherapeutic drugs and exhibits a wide spectrum of activity against solid tumors, lymphomas, and leukemias. Doxorubicin is classified as a topoisomerase II poison, although other mechanisms of action have been characterized. Here, we show that doxorubicin-DNA adducts (formed by the coadministration of doxorubicin with non-toxic doses of formaldehyde-releasing prodrugs) induce a more cytotoxic response in HL-60 cells than doxorubicin as a single agent. Doxorubicin-DNA adducts seem to be independent of classic topoisomerase II–mediated cellular responses (as observed by employing topoisomerase II catalytic inhibitors and HL-60/MX2 cells). Apoptosis induced by doxorubicin-DNA adducts initiates a caspase cascade that can be blocked by overexpressed Bcl-2, suggesting that adducts induce a classic mode of apoptosis. A reduction in the level of topoisomerase II–mediated double-strand-breaks was also observed with increasing levels of doxorubicin-DNA adducts and increased levels of apoptosis, further confirming that adducts exhibit a separate mechanism of action compared with the classic topoisomerase II poison mode of cell death by doxorubicin alone. Collectively, these results indicate that the presence of formaldehyde transfers doxorubicin from topoisomerase II–mediated cellular damage to the formation of doxorubicin-DNA adducts, and that these adducts are more cytotoxic than topoisomerase II–mediated lesions. These results also show that doxorubicin can induce apoptosis by a non-topoisomerase II–dependent mechanism, and this provides exciting new prospects for enhancing the clinical use of this agent and for the development of new derivatives and new tumor-targeted therapies. (Cancer Res 2006; 66(9): 4863-71)




This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
K. E. Coldwell, S. M. Cutts, T. J. Ognibene, P. T. Henderson, and D. R. Phillips
Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
Nucleic Acids Res., July 16, 2008; (2008) gkn439v1.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. J. Evison, F. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts
Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets
Mol. Pharmacol., July 1, 2008; 74(1): 184 - 194.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
X.-J. Wang, Z. Sun, N. F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G. T. Wondrak, et al.
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Carcinogenesis, June 1, 2008; 29(6): 1235 - 1243.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
V. Stierle, M. Duca, L. Halby, C. Senamaud-Beaufort, M. L. Capobianco, A. Laigle, B. Jolles, and P. B. Arimondo
Targeting MDR1 Gene: Synthesis and Cellular Study of Modified Daunomycin-Triplex-Forming Oligonucleotide Conjugates Able to Inhibit Gene Expression in Resistant Cell Lines
Mol. Pharmacol., May 1, 2008; 73(5): 1568 - 1577.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
B. J. Evison, O. C. Mansour, E. Menta, D. R. Phillips, and S. M. Cutts
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent
Nucleic Acids Res., June 28, 2007; 35(11): 3581 - 3589.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. M. Cutts, L. P. Swift, V. Pillay, R. A. Forrest, A. Nudelman, A. Rephaeli, and D. R. Phillips
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
Mol. Cancer Ther., April 1, 2007; 6(4): 1450 - 1459.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Zhu, M. Huang, F. Yang, Y. Chen, Z.-H. Miao, X.-H. Qian, Y.-F. Xu, Y.-X. Qin, H.-B. Luo, X. Shen, et al.
R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II
Mol. Cancer Ther., February 1, 2007; 6(2): 484 - 495.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.